logo BDSP

Base documentaire


  1. A pharmacoepidemiologic study of trandolapril.

    Article - En anglais

    In this pharmacoepidemiologic, open-label cohort study, we monitored for at least 6 months 10,820 patients with hypertension who were prescribed trandolapril by their physician.

    The drug relationships of adverse events (AEs) were assessed by the physician and then by the Knoll-France Pharmacovigilance Department.

    All AEs, other than those rated as unlikely to be causally related, were coded by both the physician and Knoll as adverse drug reactions (ADRs).

    A total of 1217 (11.25%) patients reported 1349 AEs of which 1081 (79.10%) were classified as ADRs.

    ADRs were recorded for 954 (8.82%) patients.

    After the occurrence of AEs (in 60% of patients, cough was the reason), 529 (4.89%) patients discontinued treatment.

    Serious AEs were experienced by 59 (11.2%) patients, but only 5 (0.95%) patients experienced serious ADRs.

    The most frequently reported ADRs were cough (3.57%), asthenia (1.04%), dizziness (0.92%), headache (0.74%), and nausea (0.55%). Comparison of these results with those from a 1049-patient trandolapril long-term, open-label study that was performed for the drug licensing application revealed no differences in the overall nature and frequency of serious or nonserious AEs.

    Mots-clés Pascal : Trandolapril, Antihypertenseur, Chimiothérapie, Hypertension artérielle, Traitement, Toxicité, Homme, Inhibiteur angiotensin converting enzyme, Pharmacovigilance, Etude cohorte, Epidémiologie, France, Europe

    Mots-clés Pascal anglais : Trandolapril, Antihypertensive agent, Chemotherapy, Hypertension, Treatment, Toxicity, Human, ACE inhibitor, Pharmacovigilance, Cohort study, Epidemiology, France, Europe

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0520197

    Code Inist : 002B02F05. Création : 13/02/1998.